Dr. Makis Needs Our Help & His FLORIDA Medical License Has Been APPROVED: IVERMECTIN & CANCER Part 2 - Treating Turbo Cancer With Ivermectin
💥THE MASSIVE 25% OFF WEEKEND FLASH SALE HAS BEEN EXTENDED BY ONE MORE DAY!💥
Amazing news, as the Canadian doctor that has been horribly prosecuted for curing cancer may now safely save lives in the Sunshine State:
Because unlike most oncologists, Dr. Makis actually puts cancers into total and permanent remission, which is precisely why he is still fighting legal battles in the WEF-captured communist nation of Canada after being stripped of his right to practice medicine:
Please support Dr. Makis’s work by sending a brief email to his Legal Counsel Catherine Christensen: paralegal@valourlegalactioncentre.org
As a reminder of Dr. Makis’s important oncology work, here is an article originally published last year, with this Substack’s most advanced ultimate protocol being featured at the end:
by DR. WILLIAM MAKIS MD
Last year I published one of the most popular articles on Ivermectin and Cancer Treatment ever published, which went viral internationally:
(Oct.2, 2023) - IVERMECTIN and CANCER, it has at least 15 anti-cancer mechanisms of action. Can Ivermectin Treat COVID-19 mRNA Vaccine Induced Turbo Cancers? - 9 Ivermectin papers reviewed
2024 - NEW STUDIES!
(2024 Fan et al) - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage
(2024 Man-Yuan Li et al) - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
(2024 Kaur et al) - Ivermectin: A Multifaceted drug with a potential beyond anti-parasitic therapy
(2024 Xing Hu et al) - Ivermectin as a potential therapeutic strategy for glioma
(2024 Yang Song et al) - Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
(2024 Goldfarb et al) - Lipid-Restricted Culture Media Reveal Unexpected Cancer Cell Sensitivities
(2024 Newell et al) - Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
PRACTICAL APPROACH TO USING IVERMECTIN IN CANCER TREATMENT (Disclaimer: the following is not medical advice)
In “Ivermectin and Cancer Part 1”, I covered all the mechanisms of action that Ivermectin has shown against cancer in many in vitro and in vivo studies.
The 7 new studies published in 2024 only confirm what we already know from previous studies. Ivermectin is highly effective against many cancers.
Since my previous Ivermectin article, I‘ve had 1000s of questions sent to me. Not about mechanisms of action against Cancer. But about practical use - how to use Ivermectin to treat Stage 4 Cancers, what formulations, what doses?
The goal of this article (Part 2) is to answer all of those questions to the best of my ability.
Papers reviewed:
2023 Sep.23 - Man-Yuan Li et al - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
2023 May - Samy et al - Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway
2022 Nov - Lotfalizadeh et al - The Anticancer potential of Ivermectin: Mechanisms of action and therapeutic implications
2022 Oct - Jian Liu et al - Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
2022 Jun - Daeun Lee et al - Ivermectin suppresses pancreatic cancer via mitochondria dysfunction
2021 Aug - Shican Zhou et al - Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth
2021 Jan - Mingyang Tang et al - Ivermectin, a potential anticancer drug derived from an antiparasitic drug
2019 Sep Intuyod et al - Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro
2018 Feb - Juarez et al - The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
2018 Feb - Juarez et al - The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
Satoshi Omura at the Kitasato Institute discovered Ivermectin in 1979 and was awarded a Nobel Prize in Physiology or Medicine for this discovery in 2015
Ivermectin was FDA Approved for human use in 1987 to orally treat onchocerciasis, also known as river blindness, caused by the blackfly-transmitted parasite Onchocerca volvulus
Ivermectin is annually taken by close to 250 million people
most patients treated with Ivermectin have no side-effects other than those caused by the immune and inflammatory responses against the parasite, such as fever, pruritus, skin rashes and malaise
maximum concentration in plasma is reached 4-5 h after its oral administration
its half-life is approximately 19 h and is metabolized in the liver by the cytochrome CYP1A and CYP3A4 complexes, generating 10 metabolites, mostly demethylated and hydroxylated.
Its excretion is mainly by feces and only 1% is excreted in the urine
Ivermectin exerts antitumor effects in different types of cancer.
What this means Clinically:
Chloride channel - Acute myeloid leukemia - induced cell death
Akt/mTOR path - glioblastoma, renal cancer cell lines - inhibition of mitochondrial biogenesis or function, oxidative stress, DNA damage
P2X7 (ICD) overexpression promotes tumor growth and metastases - ivermectin potentiates immunogenic cell death (ICD) in triple negative breast cancer cells
PAK1 (Autophagy) - glioblastoma and ovarian cancer cell lines - Ivermectin promotes autophagy through this pathway
WNT-TCF pathway - glioblastoma, colon cancer, melanoma - Ivermectin exerts anti-proliferative function through this pathway (possibilities to use Ivermectin to block WNT-TCF dependent cancers like breast, skin, lung)
SIN3 Domain - breast cancer (Ivermectin acts as epigenetic modulator to alter gene expression and decrease tumor growth)
NS3 helicase - glioma cells - Ivermectin had anti-tumor effects by acting as helicase inhibitor
In Vitro Studies:
breast cancer, ovarian, prostate, colon, pancreas, head and neck, melanoma - inhibits cell proliferation, induction of apoptosis, autophagy, reversion of tamoxifen resistance, inhibits metastases
glioblastoma - growth inhibition, apoptosis, and anti-angiogenesis
In Vivo Studies (done on immune deficient mice):
acute myeloblastic leukemia - reduce tumor volume up to 70%
glioblastoma - reduce tumor volume up to 50%
breast cancer - reduce tumor volume up to 60%
glioma - reduce tumor volume up to 50% (at 0.24mg/kg), however at human dose equivalent to 0.8mg/kg tumors were not detectable!
colon cancer - reduce tumor volume up to 85%
median dose employed was equivalent to 0.4 mg/kg in humans from 10 to 42 days (oral, intraperitoneal or intra-tumoral)
the in vitro and in vivo antitumor activities of Ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies done in healthy and parasited patients
2019 Sep Intuyod et al - Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro
Ivermectin studied on cholangiocarcinoma cells that were chemo resistant (gemcitabine)
Ivermectin inhibited cancer cell proliferation and colony formation in a dose and time dependent manner(!)
Ivermectin caused S-phase cell cycle arrest and cell death
Conclusion: “Ivermectin might be useful as an alternative treatment for cholangiocarcinoma, especially in patients who do not respond to chemo.”
2021 Jan - Mingyang Tang et al - Ivermectin, a potential anticancer drug derived from an antiparasitic drug
specific mechanism of IVM-mediated cytotoxicity in tumor cells is unclear; it may be related to the effect of IVM on various signaling pathways
IVM seems to induce mixed cell death in tumor cells
CONCLUSIONS: Ivermectin selectively inhibits the proliferation of tumors at a dose that is not toxic to normal cells and can reverse the MDR (multi-drug resistance) of tumors.
In healthy volunteers, the dose was increased to 2 mg/kg, and no serious adverse reactions were found
Unfortunately, there have been no reports of clinical trials of IVM as an anticancer drug
large number of research results indicate that IVM affects multiple signaling pathways in tumor cells and inhibits proliferation, IVM may cause antitumor activity in tumor cells through specific targets
Ivermectin regulates the tumor microenvironment, inhibits the activity of tumor stem cells and reduces tumor angiogenesis and tumor metastasis.
It has become increasingly clear that Ivermectin can induce a mixed cell death mode involving apoptosis, autophagy and pyroptosis depending on the cell conditions and cancer type.
Ivermectin can enhance the sensitivity of chemotherapeutic drugs and reduce the production of resistance. Therefore, IVM should be used in combination with other drugs to achieve the best effect
2022 Jun - Daeun Lee et al - Ivermectin suppresses pancreatic cancer via mitochondria dysfunction
Poster presentation from South Korea
Ivermectin was combined with gemcitabine in pancreatic cancer
Ivermectin-gemcitabine combination inhibited pancreatic cancer cell proliferation via G1 arrest of cell cycle
in vivo experiments showed ivermectin-gemcitabine significantly suppressed tumor growth of pancreatic cancer compared with gemcitabine alone
Conclusion: “Ivermectin could be a potential antitumor drug for the treatment of pancreatic cancer”
2021 Aug - Shican Zhou et al - Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth
Colorectal cancer is 3rd most common cancer worldwide, lacks effective therapy
Ivermectin tested on colorectal cancer cell lines
Ivermectin dose-dependently inhibited colorectal cancer growth
promoted cell apoptosis
promoted total and mitochondrial ROS production (reactive oxygen species)
induced colorectal cancer cell S-phase arrest
Conclusion: Ivermectin might be a new potential anticancer drug therapy for human colorectal cancer
2022 Oct - Jian Liu et al - Progress in Understanding the Molecular Mechanisms Underlying the Antitumor Effects of Ivermectin
PAK1 (Autophagy) - Ivermectin, acts as PAK1 inhibitor and inhibits growth of breast cancer, ovarian cancer, glioblastoma and NF2 tumors and involved in cell death in Nasopharyngeal carcinoma and melanoma.
Apoptosis (Caspase Dependent) - Ivermectin induces apoptosis in glioblastoma, chronic myeloid leukemia cells, also breast cancer, ovarian cancer.
Immunogenic Cell Death (ICD - P2X7 signaling) - ivermectin induces cell death in triple negative breast cancer.
YAP1 Inhibition - hepatocellular and cholangiocarcinoma, colorectal cancer, ovarian cancer, gastric cancer - ivermectin exerts anti-tumor effects
WNT Path (cancer progression - differentiation, metastasis, cell senescence, tumor initiation, tumor growth) - Ivermectin inhibits this path - inhibits colon cancer and lung cancer, ivermectin also limits formation of cancer stem cells.
TF3 Path - ivermectin stimulates apoptosis of melanoma cells.
RNA Helicase Inhibition - ivermectin inhibits cell invasion and proliferation of glioma cells
SID Peptide (SIN3A/B) - Ivermectin inhibits breast cancer progression, also restores tamoxifen sensitivity
Akt/mTOR inhibition - Ivermectin inhibits mitochondrial respiration - glioblastoma, CML leukemia (some cancers like breast, leukemia and lymphoma are more metabolically active and depended on mitochondria - more responsive to ivermectin inhibition)
ivermectin is an angiogenesis inhibitor
ivermectin has anti-mitotic activity
In humans, toxicity of ivermectin is very low, no serious adverse reactions have been found in healthy volunteers at dose up to 120 mg (~2 mg/kg) (Reference: GuzzoCA, FurtekCI, PorrasAG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122–1133.)
2023 May - Samy et al - Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway
Ivermectin (derivative) inhibits prostate cancer cell viability, migration capacities
Ivermectin induces apoptosis, autophagy (via ROS)
Ivermectin downregulates expression of cancer stem cell markers
Conclusion: Ivermectin has tremendous potential to target metastatic prostate cancer cells and provides new avenues for therapeutic approaches to advanced prostate cancer
2023 Sep.23 - Man-Yuan Li et al - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
Ivermectin was studied on lung adenocarcinoma cells
Ivermectin strikingly impeded colony formation and viability of cancer cells, along with cell proliferation, caused apoptosis and enhanced autophagy
Ivermectin efficiently suppressed cellular growth of lung adenocarcinoma cells in vivo among nude mice
My Take…
Ivermectin exerts anti-cancer effects through at least 15 different pathways proven in the medical literature, both in vitro and in vivo!
(You get a nice summary of these 15 pathways from the 2021 paper by Mingyang Tang et al.)
First, let’s quickly summarize the anti-cancer mechanisms (a quick summary can be found in 2022 paper by Loftalizadeh et al):
Ivermectin induces tumor cell death: apoptosis, autophagy, pyroptosis
Ivermectin inhibits tumor initiation and tumor progression (via WNT inhibition, YAP1 inhibition)
Ivermectin inhibits tumor growth and proliferation (via Akt/mTOR inhibition, MAPK inhibition)
Ivermectin stops cancer cell migration, invasion and metastasis (via PAK1 inhibition - seen in 70% of all cancers, EMT inhibition, RNA Helicase inhibition)
Ivermectin causes cancer cell mitochondrial dysfunction (inhibits mitochondrial biogenesis, increases reactive oxygen species selectively only in cancer cells)
Ivermectin regulates tumor microenvironment (to inhibit tumor growth and progression, via P2X7 path, ICD - mediates immunogenic cell death)
Ivermectin inhibits cancer stem cells (which are responsible for tumor initiation, progression and recurrence)
Ivermectin inhibits tumor angiogenesis (tumor blood vessel creation)
Ivermectin has anti-mitotic activity (interacts with mammalian tubulin)
Ivermectin is an epigenetic regulator of cancer to inhibit cancer progression (alters gene expression to inhibit cancer progression, SIN3A, EMT)
Ivermectin can overcome tumor multidrug resistance
What cancers can Ivermectin treat?
The top 5 COVID-19 mRNA Vaccine Induced Turbo Cancers are: lymphomas, brain cancers, breast cancers, colon cancers and lung cancers (signals also seen in leukemias, hepatobiliary cancers, testicular cancers, sarcomas and melanomas)
Ivermectin has been shown to kill these cancer cells (in vitro or in vivo):
breast cancer, especially triple negative breast cancer which is often seen in COVID-19 mRNA Vaccinated women and has the worst prognosis.
glioblastoma and gliomas (glioblastomas are often seen in COVID-19 mRNA Vaccinated individuals)
leukemias, both AML and CML (these are the most aggressive and quickly lethal mRNA Turbo Cancers)
colorectal cancer (Stage 4 Colon cancers common in COVID-19 mRNA vaccinated)
hepatobiliary cancers: hepatocecullar carcinoma, cholangiocarcinoma, pancreatic cancer (major signal with COVID-19 mRNA Vaccines)
lung cancer (Stage 4 lung cancers in COVID-19 mRNA Vaccinated)
melanoma (definite signal in COVID-19 mRNA vaccinated)
renal cell cancer (possible signal with mRNA Turbo Cancers) and urothelial carcinoma
ovarian cancer (possible signal with mRNA Turbo Cancers)
prostate cancer (possible signal with mRNA Turbo Cancers)
There is almost no literature on Ivermectin and lymphomas which are probably the most common COVID-19 mRNA vaccine turbo cancers - this must be investigated.
What dose of Ivermectin to treat COVID-19 mRNA Vaccine Turbo Cancer?
Guzzo et al published a paper in 2022 on the “Safety, tolerability, and pharmacokinetics of escalating high doses of Ivermectin in healthy adult subjects”
The highest dose tested to be safe with no side effects, was 2 mg/kg.
Max concentration in plasma is 4 hours after oral intake
Half life is 18 hours
Dr.David E. Scheim PhD, Blacksburg VA also wrote an interesting article on Ivermectin Safety in Sep.7, 2021 (Source)
Several studies have shown that Ivermectin’s anti-cancer effects are DOSE-DEPENDENT (higher dose = better response)
Warning: not to be taken as medical advice - hypothetical situation: if I was faced with a COVID-19 Vaccine Induced Turbo Cancer or an advanced stage cancer, I would be looking at an Ivermectin dose of 2mg/kg orally, daily or every two days.
Dr. Justus Hope MD published an article on Aug.29, 2023 that discusses anecdotal cases of Stage 4 Colon cancer, Stage 4 Ovarian Cancer responding to Ivermectin with dramatic drop in Tumor markers.
High-dose Ivermectin shrinks cancer metastases
Also mentioned is a “High Dose Ivermectin” regimen of 2mg/kg per day for a doctor with Stage 4 Gallbladder cancer, taken for over a year, with visual side effects for a few days initially which resolved.
Also described is a case of enlarged Prostate suspicious for cancer, and a 5 week Ivermectin 45mg/day regimen that dropped PSA from 89.1 to 10.9 with resolution of nocturnal urinary frequency. For a 100kg man, that is a dose of 0.45mg/kg, significantly lower than the 2 mg/kg safe dose published by Guzzo et al.
The article describes a cancer patient with a neck tumor and lung metastases on a High Dose Ivermectin regimen of 2.45mg/kg daily.
I believe that it is a reasonable hypothesis that COVID-19 mRNA Vaccine Turbo Cancer patients could benefit from High Dose Ivermectin regimens, such as 2mg/kg and we urgently need more research to be done in this area.
(mRNA Vaccine Induced Turbo Cancers such as leukemias, glioblastomas, breast cancers (including triple negative), colon cancers, hepatobiliary cancers, lung cancers, melanomas, renal cell cancers, ovarian cancers, prostate cancers - as there is already evidence in the literature)
Based on the above information, if one were afflicted with “vaccine” induced turbo cancer, then one could greatly increase the Ivermectin dose (i.e. 2mg/kg) in the below treatment, as well as double or even quadruple the Fenbendazole dose with no toxicity whatsoever:
The Ultimate Disease Cure & Prophylaxis Protocol
Tocotrienol and Tocopherol forms (all 8) of Vitamin E (400-800mg per day, 7 days a week). A product called Gamma E by Life Extension or Perfect E are both great.
Bio-Available Curcumin (600mg per day, 2 pills per day 7 days a week). A product called Theracurmin HP by Integrative Therapeutics is bioavailable.
Vitamin D (62.5 mcg [2500 IU] seven days a week).
CBD oil (1-2 droppers full [equal to 167 to 334 mg per day] under the tongue, 7 days a week) CBD-X: The most potent full spectrum organic CBD oil, with 5,000 milligrams of activated cannabinoids and hemp compounds CBD, CBN & CBG per serving.
Fenbendazole (300mg, 7 days a week) or in the case of severe turbo cancers up to 1 gram — for prophylaxis one 150mg tablet once or twice per week
Ivermectin (24mg, 7 days a week) or in the case of severe turbo cancers up to 1mg/kg/day — for prophylaxis one 12mg tablet once or twice per week
Hydroxychloroquine (10mg/kg/day 7 days a week) - for prophylaxis one 200mg tablet once or twice per week
Doxycycline (100mg, 7 days a week for 30-60 days)
VIR-X immune support which also greatly increases the bioavailability of both Fenbendazole and Hydroxychloroquine (2 capsules per day) — for prophylaxis 2 capsules per day
Removing sugars and carbohydrates (cancer food) from your diet and replacing table sugar with a zero glycemic index, zero calorie, keto friendly rare sugar like FLAV-X
Please note that Hydroxychloroquine was recently added to this protocol, and for very good reason; to wit:
Do NOT comply.
THE MASSIVE 25% OFF WEEKEND FLASH SALE has been extended by one more day, so please use code MASSIVE25 to receive 25% off on the newest product Hydroxychloroquine, as well as ALL of the amazing lifesaving products that you have been purchasing for many years now like the Nobel Prize winning miracle compound Ivermectin, the no less miraculous Fenbendazole, Doxycycline, the full spectrum organic CBD oil containing 5,000 milligrams of activated cannabinoids and hemp compounds CBD, CBN & CBG, the powerful immune support nutraceutical and spike support formula VIR-X, and the sugar craving reducing, blood sugar balancing and even anti-cancer allulose sugar substitute FLAV-X!
THE MASSIVE 25% OFF WEEKEND FLASH SALE ends TONIGHT, February 9th (midnight eastern time), 2026.
Upon adding products to your cart, please go to the cart icon at the top right corner of your browser page and click it, then choose the VIEW CART option whereby you will be redirected to a page where you can enter the code MASSIVE25 in the Use Coupon Code field.
Only the RESOLVX HEALTH website offers all of the authentic products that this Substack promotes.
Please contact the company directly with any product questions: info@resolvx.health
Hurry on down here, Dr. Makis, and let me know when you need a nurse!
Hi Dr. Makis James here with the Medical Truth Podcast! I interviewed you on the podcast 3 years ago! Any idea as to what part of Florida you will be setting up your practice in? Keep me posted!!
https://medicaltruthpodcast.com/post-vaccine-injury-interview-with-william-makis-md/